Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] What must be the role of INSERM in French biomedical research?

The major criticism raised in an Editorial (June 16, p 2390)1 was the suggestion that the renewal of the Chief Executive Officer (CEO) at the French National Institute of Health and Medical Research (INSERM) lacks transparency, since the candidates for the position are not known. This suggests that the practice does not support an “open and transparent nomination process”.1 One must remember that in France, candidates are protected by the legal framework; they are auditioned and judged by a jury, and a candidate is proposed to the appropriate ministry.